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INTRODUCTION
S
ince the isolation of the first bisintercalator natural
product, echinomycin,1 in 1957 eighteen additional
members have been added to this family of com-
pounds (see Figure 1). These microbial secondary
metabolites have been found in a variety of bacterial
strains including several Streptomyces, some Micromonospora,
Actinomadura, and Nocardioides. In some instances, the same
compounds were isolated from a number of distinct bacterial
species. For example, after being discovered in Streptomyces
echinatus sp. 1,1 echinomycin, also termed quinomycin A, was
detected as a metabolite of Streptomyces sp. 732,2 and later on
as a product of Streptomyces sp. KN-06473 and Streptomyces
lasaliensis.4 For many years, their potent activity as antitumors,
antivirals, and antibiotics, as well as a desire to understand
how they target DNA contributed to a continued interest in
these compounds. More recently, it is the aim to decipher how
Nature produces these bisintercalating products and to identify
novel potent lead compounds for clinical applications that has
sustained the interest in this family of compounds.
Based on the structure of their nonribosomally biosynthe-
sized peptidic core, these compounds can be divided into
three classes: (i) cyclic, (ii) twofold symmetric bicyclic, and
(iii) pseudosymmetric bicyclic. The main difference between
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ABSTRACT:
The bisintercalator natural products are a family of
nonribosomal peptides possessing a range of biological
properties that include antiviral, antibiotic, and
anticancer activities. The name bisintercalator is derived
from the ability to directly bind to duplex DNA through
two planar intercalating moieties. Although 19 members
of this family of compounds have been identified over the
past 50 years, the biosynthetic genes responsible for the
formation of four of these molecules (thiocoraline, SW-
163, triostin A, and echinomycin) were identified only
recently. This recent progress opens an avenue towards
understanding how Nature produces these
bisintercalating products and provides the potential to
develop and identify novel potent analogous lead
compounds for clinical applications. This review discusses
the mode of action of bisintercalators and summarizes
recent genetic and biochemical insights into their
biosynthetic production, analog formation, and possible
mechanisms by which resistance to these compounds is
achieved by their producing organisms. # 2010 Wiley
Periodicals, Inc. Biopolymers 93: 777–790, 2010.
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FIGURE 1 Structures of bisintercalator natural products with their key pharmacophores for
DNA intercalation colored in red (3-hydroxyquinaldic acid, 3HQA), blue (quinoxaline-2-carboxylic
acid, QXC), green (6-methoxy-3-hydroxyquinaldic acid), and orange (6-methoxy-quinoxaline-2-
carboxylic acid). Their producing organisms are presented into parentheses.
the symmetric and pseudosymmetric bicyclic molecules is
the identity of their central linker, a disulfide bond, and a thi-
oacetal bridge, respectively. Members of the cyclic bisinterca-
lators include the luzopeptins,5,6 the quinoxapeptins,7 qui-
naldopeptin,8 and sandramycin.9,10 The twofold symmetric
bicyclic class comprises BE-22179,11 thiocoraline,12,13 quino-
mycin B and C,14 SW-163C,15,16 and triostin A.17,18 The
pseudosymmetrical SW-163D-G19 and echinomycin are
derived from SW-163C and triostin A, respectively. The pep-
tidic core of all of these compounds is further decorated with
two planar heteroaromatic units [3-hydroxyquinaldic acid
(3HQA) for thiocoraline, BE-22179, sandramycin, quinaldo-
peptin, and the SW-163s; quinoxaline-2-carboxylic acid
(QXC) for the quinomycins and triostin A; 6-methoxy-3-
hydroxyquinaldic acid for the luzopeptins; and 6-methoxy-
quinoxaline-2-carboxylic acid for the quinoxapeptins] essen-
tial for biological activity through binding to duplex DNA by
bisintercalation.
The isolation, structure determination, and biological activ-
ity of most of the members of the family of bisintercalator nat-
ural products have been recently reviewed.20 These topics will
not be covered in this review, which is meant to focus primar-
ily on the recent literature (2006–2010) related to the mode of
action and the biosynthesis of these compounds, the produc-
tion of their analogs, and the possible mechanisms by which
resistance to them is conferred to their producing organisms.
MODE OF ACTION: DNA
BISINTERCALATION
A large number of classes of synthetic and naturally occurring
compounds exert their biological activity through one of three
DNA-binding modes: (i) covalent binding, (ii) nonintercala-
tive groove binding, and (iii) intercalation.21 As their name
implies, the bisintercalator natural products, with their cyclic
peptidic backbone and two planar chromophores, possess the
ability to bisintercalate tightly into DNA. Their interactions
with their target DNA have been studied using a variety of
techniques including DNase I footprinting, fluorescence
quenching, surface plasmon resonance, NMR, X-ray crystal-
lography, and, more recently, electrospray ionization tandem
mass spectrometry.22,23 In general, sandwiching of two bases
between the two heteroaromatic units has been shown to ulti-
mately lead to proper placement of the peptidic core, held by
van der Waals interactions and mainly by hydrogen bonding
with base pairs, into the DNA minor groove.24 The amino
acid composition of the peptidic backbone has been found to
play an important role in dictating the binding sequence speci-
ficity of these molecules. The nature of the central cross-bridge
(disulfide vs thioacetal) is also crucial in determining DNA
sequence selectivity.25 The effect of local DNA sequence on the
interaction of the bisintercalators with their preferred binding
sites has been studied.26
Bisintercalators with 50-GC Selectivity
DNase I footprinting experiments showed that echinomycin
preferentially binds at 50-GC sites.27 The molecular details of
the interaction of echinomycin with DNA have been deter-
mined by a number of structural studies by X-ray crystallogra-
phy and NMR, and confirmed a preference for AT base pairs
at sites that flank the primary binding sites.28–35 In echinomy-
cin-DNA complexes, the base pairs next to the 50-GC site are
almost always exclusively in the Hoogsteen mode, with some
rare Watson-Crick exceptions. Footprinting and NMR studies
indicated that like echinomycin, SW-163G, previously termed
UK-63052 or QN, mostly binds at 50-GC sites.36 However, in
contrast to what is observed with echinomycin, only the usual
Watson-Crick base pairs flank the bisintercalation site as
revealed by a solution structure of a SW-163G-DNA oligomer
complex. Binding of SW-163G to DNA is also more sensitive
to the nature of the surrounding sequence when compared
with echinomycin binding profiles. Until recently, even though
a weak preference toward 50-GC sites was observed, attempts
to establish a clear sequence selectivity of DNA binding for
thiocoraline were unsuccessful.37 The binding preference for
GC-rich sequences highly similar to those of echinomycin was
unambiguously confirmed in 2007 by classical DNase I foot-
printing, fluorescence melting experiments, and X-ray crystal-
lography.38 The crystal structure of thiocoraline revealed a
novel and unique arrangement of stacked arrays of docked
pairs of staple-shaped molecules suggesting how the DNA
bisintercalation occurs.
Bisintercalators with 50-AT Selectivity
In contrast to echinomycin, SW-163G, and thiocoraline,
which all display 50-GC selectivity, luzopeptin A, sandramy-
cin, triostin A, and TANDEM (a synthetic N-demethylated
analog of triostin A, Figure 1) were found to bind with high
affinity to AT-rich DNA. The luzopeptins do not display rigid
sequence selectivity, and as for SW-163G, no evidence for
Hoogsteen base-pairing was observed by NMR in a luzopep-
tin A-d(50-GCATGC)2 complex.
39 Studies by fluorescence
quenching40 and surface plasmon resonance41 showed that,
in many respects, the mode of interaction with DNA of san-
dramycin is very similar to that of luzopeptin A with the
exception that sandramycin displays overall higher sequence
selectivity. Interestingly, triostin A, a direct precursor of echi-
nomycin, was shown to favor AT-rich DNA sequences over
the GC-rich DNA species, illustrating the importance of the
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nature of the central linker (disulfide vs thioacetal) of these
molecules.25
BISINTERCALATORS BIOSYNTHESIS
The gene cluster sequences for four of the known bisintercala-
tor natural products (thiocoraline,42 SW-163,43 triostin A,44
and echinomycin45) have recently been determined (see Figure
2). Not surprisingly, considering the similar structural organi-
zation of these molecules, the reported gene clusters are
remarkably similar in gene composition. All clusters comprise
7 to 10 proteins (highlighted in blue in Figure 2) that could be
involved in the initial construction of the heteroaromatic
chromophores 3HQA and QXC. They also include two nonri-
bosomal peptide synthetases (NRPSs) (highlighted in red in
Figure 2) from which the peptidic backbone of these com-
pounds is proposed to arise after initiation by activation of the
starter units 3HQA and QXC. Additional peptide modification
enzymes (shown in purple and pink in Figure 2) are also sug-
gested to be involved in peptidic core formation.
Generation of the 3HQA and QXC Appendages
Early efforts at determining the origin of the QXC chromo-
phores of triostin A by 14C-labeled tryptophan feeding studies
established L-Trp as a likely precursor of QXC.46 In a similar
manner, using 15N-labeled amino acids, the QXC of echino-
mycin was confirmed to be derived from L-Trp.47 The forma-
tion of 6-fluoro-QXC during feeding studies with D,L-5-fluoro-
tryptophan led to the proposal that the carbon at position 6
(C6) of QXC corresponds to the C5 of the indole ring of
L-Trp.48 More recent feeding, NMR, and mass spectrometry
experiments using chemically synthesized (2S,3S)-5-deutero-
b-hydroxy-L-Trp identified it as a key intermediate in echino-
mycin production. Based on these preliminary studies and the
various genes found in the cluster for echinomycin and trio-
stin A, a biosynthetic pathway involving eight proteins (TrsR,
H, B, Q, C, F, O, and P for triostin A; Ecm13, 8, 12, 2, 11, 14,
4, and 3 for echinomycin) has been put forth for the biosyn-
thesis of their QXC chromophore (Figure 3C).44,45 The initial
steps leading to the b-hydroxy-L-Trp intermediate are thought
to commence with activation of L-Trp to L-Trp-AMP by the
adenylation domain of the standalone A-T didomain TrsR/
Ecm13 followed by its covalent attachment to the T domain of
the enzyme. Hydroxylation of the b-carbon of L-Trp and
release of the b-hydroxy-L-Trp by the type II thioesterase (TE)
TrsQ/Ecm2 are the likely subsequent steps en route to QXC.
The remaining stages of the QXC pathway require opening of
the indole ring of b-hydroxy-L-Trp. Similarly to the first rate-
limiting step during tryptophan catabolism in which L-Trp is
converted to N-formylkynurenine,49–51 oxidative cleaving of
the C2C3 bond of the pyrrole ring of b-hydroxy-L-Trp and
incorporation of both atoms of molecular oxygen could be
achieved by action of TrsC/Ecm11. Three additional enzymes
are proposed to complete the QXC formation. TrsF/Ecm14
could produce b-hydroxykynurenine by deformylation, which
could then be oxidatively cyclized and hydrolyzed by TrsO/
Ecm4. TrsP/Ecm3 would be responsible for the final enzyme-
catalyzed oxidation prior to spontaneous decarboxylation,
imine formation, and oxidative aromatization to generate
QXC. The MbtH-like protein TrsH/Ecm8 for which the exact
biological function still remains to be determined could
potentially also be involved in QXC formation. As of now,
none of the steps involved in QXC production have been bio-
chemically confirmed.
The production of the 3HQA chromophore of thiocoraline
and SW-163C could proceed by one of two routes from the
L-Trp precursor (Figures 3A and 3B). In the first route (Figure
3B), in a manner similar to that proposed for QXC formation,
L-Trp is converted to b-hydroxykynurenine by consecutive
action of the TioK/Swb11, TioI/Swb13, TioP or Q/Swb14, TioF/
FIGURE 2 Genetic organization of the thiocoraline (tio), SW-163 (swb), triostin A (trs), and echi-
nomycin (ecm) gene clusters.
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FIGURE 3 A and B: Two possible pathways for 3HQA biosynthesis during thiocoraline and SW-
163 formation. The enzymes involved in thiocoraline and in SW-163 are indicated in red and blue,
respectively. C: Proposed QXC biosynthesis during triostin A and echinomycin formation. The
enzymes involved in triostin A and echinomycin are indicated in orange and green, respectively.
The / indicates that either of the two enzymes proposed could perform the reaction.
Swb10, and TioL or TioM enzymes. The presence of two poten-
tial type II TE domains (TioP and TioQ) is unique to the thio-
coraline gene cluster. Based on sequence alignment, TioQ is
suggested to be the active unloading TE enzyme. No genes cod-
ing for enzymes with kynurenine formamidase activity have
been identified in the thiocoraline or SW-163C clusters. TioL or
TioM have been suggested as potential candidate for the defor-
mylation reaction in thiocoraline biosynthesis. No homologs of
TioL or TioM have been found in the SW-163C gene cluster.
The transformation of b-hydroxykynurenine into 3HQA would
then occur by cyclization by the kynurenine aminotransferase
TioG and final elimination of the 4-hydroxy moiety by TioH.
Alternatively, 3HQA could arise by a series of rearrangements
that would utilize only five (TioF, TioL or M, TioG, TioH, and
TioI) of the eight enzymes of the first pathway. In this route,
the Trp 2,3-dioxygenase (TDO) TioF/Swb10 is the first enzyme
to take action. TDOs are known to be highly specific for the L-
Trp substrate.52 For that reason, the latter strategy was originally
favored (Figure 3A). However, it was recently demonstrated
that TioF is a unique Trp 2,3-dioxygenase that is active against a
variety of substrates including L-Trp, D-Trp, serotonin, and
indole53 as well as 5-fluoro-D,L-Trp, 6-fluoro-D,L-Trp, and 6-
methyl-D,L-Trp (unpublished data). In conjunction with the
preliminary data revealing (2S,3S)-5-deutero-b-hydroxy-L-Trp
as a key intermediate during QXC formation, this result sug-
gests the first pathway (Figure 3B) as a more plausible mecha-
nism for 3HQA production. Further biochemical studies
remain to be accomplished to confirm and gain a more
advanced appreciation of the intriguing logic of molecular as-
sembly of the 3HQA and QXC chromophores.
Peptidic Core Biosynthesis Initiated by Attachment
of the 3HQA and QXC Chromophores
The bisintercalators’ peptidic cores are biosynthesized by
nonribosomal peptide synthetase (NRPS) assembly-lines (see
Figure 4). NRPSs are multifunctional modular enzyme com-
plexes, with each module responsible for adding a specific
amino acid monomer to the growing peptide chain. The bio-
synthesis of nonribosomal peptides (NRPs) by NRPSs com-
prises several repeating steps based on the catalytic action of
three essential components found in each NRPS elongation
module: an adenylation (A), a thiolation (T), and a conden-
sation (C) domain.54–56 Adenylation (A) domains are
involved in activation of the carboxylic group of the amino
acid (or aryl acid) substrate through an ATP-dependent reac-
tion that results in an aminoacyl-AMP intermediate,57 which
is subsequently readily transferred to the 40-phosphopante-
theinyl (Ppant) arm of the active (holo) downstream T do-
main partner. The successive amino acids are then joined by
the formation of amide bonds catalyzed by C domains. The
formation of NRP natural products proceeds in three distinct
phases: initiation, elongation, and termination.
Early feeding studies in S. triostinicus and S. echinatus
using several structural analogs of QXC revealed that QXC
acted as a free intermediate during triostin A and echinomy-
cin biosynthesis.48,58–61 In line with this observation, Keller
and coworkers isolated and characterized the enzyme that
activates QXC to QXC-AMP in S. triostinicus and S. echina-
tus.62 It was therefore proposed that during the biosynthesis
of bisintercalator natural products the initiation occurs by
activation of the starter units 3HQA and QXC by an adeno-
sine monophosphate (AMP) ligase, followed by their cova-
lent attachment to a standalone T domain. TioJ and Swb12
are proposed to activate 3HQA for initiation of thiocoraline
and SW-163C biosynthesis, respectively, whereas TrsA and
Ecm1 are suggested to convert QXC to QXC-AMP to initiate
triostin A and echinomycin formation. Unique to the thio-
coraline cluster is the presence of an independent T domain,
TioO, proposed to be responsible for covalent tethering of
the 3HQA prior to its condensation with the D-Cys attached to
the T1 domain of the TioR loading module. It was proposed
that during the production of echinomycin, triostin A, and SW-
163C, an acyl carrier protein from the fatty acid biosynthesis
enzymatic complex, FabC, is recruited to play this role.43–45
Functional group and structural diversity is introduced
into NRPs by two ways: (i) by utilizing a diverse monomer
pools that includes not only the 20 naturally occurring
amino acids, but also a large number ([300) of unnatural
amino and aryl acid substrates,63 and (ii) by the use of auxil-
iary domains strategically embedded into specific modules of
the NRPS assembly lines. The primer unit 3HQA found in
thiocoraline and SW-163 as well as the bisintercalating chro-
mophore QXC of echinomycin and triostin A are representa-
tive examples of unnatural aryl acid substrates used during
bisintercalators production. An additional nonproteinogenic
amino acid, (1)-(1S,2S)-norcoronamic acid ((1)-NCA), is
also found in the SW-163 family of compounds. Two pro-
teins, the PLP-dependent aminotransferase Swb6 and the
radical SAM protein Swb7, could potentially mediate the as-
sembly of (1)-NCA from L-Val via radical cyclopropanation
(see Figure 5). Even though the monomer composition of
their peptidic core differs (D-Cys, Gly, N-Me-L-Cys, and N,S-
diMe-L-Cys for thiocoraline; D-Ser, L-Ala, N-Me-L-Cys, and
N-Me-L-Val for triostin A and echinomycin; and D-Ser, L-Ala,
N-Me-L-Cys, and N-Me-NCA for SW-163C), the NRPSs’ do-
main organizations of the elongation modules for thiocora-
line, echinomycin, triostin A, and SW-163C are identical (see
Figure 4). These bisintercalator natural products are biosyn-
thesized on two NRPSs (TioR/S for thiocoraline; Swb16/17
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FIGURE 4 Structural organization of the (A) thiocoraline NRPSs, (B) echinomycin and triostin
A NRPSs, and (C) SW-163C NRPSs. Each module of the NRPSs is represented by a different color.
In panel B, the enzymes for echinomycin and triostin A biosynthesis are represented by Ecm and
Trs, respectively. Abbreviations used: A, adenylation domain; C, condensation domain; E, epimeri-
zation domain; L, AMP-ligase; M, N-methyltransferase domain; T, thiolation domain (T domains
have also been denoted in the literature as peptidyl carrier protein [abbreviated as PCP, PC, or P]
and carrier protein [CP] domains); TE, thioesterase domain.
for SW-163; TrsJ/I for triostin A; and Ecm6/7 for echinomy-
cin), each composed of two modules with C1-A1-T1-E1-C2-
A2-T2 and C3-A3-M3-T3-C4-A4-M4-T4-TE framework. The
auxiliary epimerization (E) domain of the loading module is
responsible for the L- to D-inversion of configuration after
the covalent attachment of the L-amino acid to T1 and prior
to its condensation with the bisintercalating unit mediated
by C1. The methyltransferase (M) domains embedded into
modules 3 and 4 are proposed to be involved in N-methyla-
tion of L-Cys, L-Val, and NCA during the biosynthesis of the
four studied bisintercalators. TioN, an A domain interrupted
between motifs A2 and A3 by the M1 core of an M domain,
could be responsible for S-methylation during thiocoraline
formation.
Finally, the terminal TE domain is proposed to homo-
dimerize, cyclize, and release the peptidic chain prior to the
disulfide bond formation potentially catalyzed by the oxidor-
eductases Ecm17, TrsN, and Swb20 during echinomycin, tri-
ostin A, and SW-163C biosynthesis, respectively. No corre-
sponding oxidoreductase enzyme has been found in the thio-
coraline cluster. Further conversion of triostin A into
echinomycin and of SW-163C into SW-163D could be
accomplished by disulfide bond rearrangement by the SAM-
dependent methyltransferases TrsK, Ecm18, and Swb8. The
activity of Ecm18 was confirmed in vitro,45 but the activity of
TrsK and Swb8 remains to be proven. Preliminary feeding
studies using [methyl-D3]-L-Met support subsequent step-
wise additions of methyl groups for the formation of SW-
163E-G from SW-163C by the radical SAM protein Swb9.43
BISINTERCALATOR ANALOGS
The desire to generate novel bisintercalators as novel phar-
maceutically important compounds motivates our under-
standing of the details governing their mode of action. Since
the isolation of the first bisintercalators, a number of
researchers have investigated new ways to produce these
compounds and their analogs. In the early days more tradi-
tional synthetic methods were used for the total synthesis of
naturally occurring scaffolds and analogs production. Trio-
stin A N-DEMethylated (TANDEM)64,65 and triostin A66
were the first to be synthesized. Boger et al. have chemically
generated thiocoraline,37,67 BE-22179,37,67 sandramycin,68
the luzopeptins,69,70 the quinoxapeptins,71 and their respec-
tive analogs.40,41,72 A detailed review of the early syntheses
and the insights gained from these studies has been pub-
lished.20 Here, we will focus on the latest analogs and the
novel methodology used for their production. With echino-
mycin recently found to exhibit high activity against methi-
cillin-resistant Staphylococcus aureus (MIC 5 0.03 lM) and
against biofilm-forming Enterococcus faecalis (MIC 5 0.01
lM) the interest in the bisintercalators’ biological properties
has increased.73,74 The access to the bisintercalator biosyn-
thetic machineries has permitted the chemoenzymatic pro-
duction and the biosynthetic engineering of novel analogs of
this family of compounds.
Synthetic Analogs
In the last 5 years, the chemical syntheses of bicyclic depsi-
peptide analogs have mainly focused on the triostin A and
thiocoraline scaffolds. The synthetic challenges encountered
during triostin A synthesis are associated with the presence
of consecutive N-methylated amino acids and two ester
bonds that favor diketopiperazine formation. These difficul-
ties were overcome by a new concept of protection referred
to as conformationally restricted mobility as exemplified dur-
ing the first solid-phase synthesis of triostin A (see Figure
FIGURE 5 Possible biosynthetic pathway for (1)-NCA formation from L-Val. Abbreviations
used: Ado-CH3, 5
0-deoxyadenosine; PLP, pyridoxal-50-phosphate; SAM, S-adenosyl-L-methionine.
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6).75 The main idea is to form an inter-chain disulfide bridge
that restricts the mobility of the peptide chain and prevents
diketopiperazine formation. The thiocoraline analog oxa-
thiocoraline (see Figure 1) with esters in place of the thio-
ester moieties was also prepared using this strategy.76 A
manuscript on the lessons to be learned from the synthesis of
complex N-methylated depsipeptides such as oxathiocoraline
has been published last year.77 In sum, the following factors
should be taken into account: (i) the solid support (e.g., the
choice of the resin is critical and CTC should be favored over
Wang resin as it will minimize the risk of diketopiperazine
formation), (ii) the protecting groups (e.g., Alloc and pNZ
groups should be used instead of Fmoc as they also will also
prevent diketopiperazine formation, however these groups
can only be used at specific positions on the peptide chain),
(iii) the identity of the C-terminal amino acid, (iv) the
coupling reagents (e.g., HATU gives the best yields when
coupling N-methylated amino acids), and (v) the cleavage
cocktail.
Analogs of thiocoraline with amide (azathiocoraline) and
N-methylated amide (NMe-azathiocoraline) moieties in
place of the thioester groups have also been synthesized (see
Figure 1). Two solid-phase strategies, a convergent [4 1 4]
approach and a stepwise synthesis, were designed to generate
azathiocoraline (see Figure 7).78 The [4 1 4] fragment cou-
pling method was also used to synthesize NMe-azathiocora-
line, which was found to display an increased stability in
human serum when compared to thiocoraline.79 Using N-
methyl amides as isosteres for ester or thioester bonds
preserves hydrogen bonding properties; this idea could be
used as a general strategy to prepare other bisintercalator
FIGURE 7 Two solid-phase strategies used for azathiocoraline production.
FIGURE 6 Schematic representation of (A) diketopiperazine
formation, and (B) prevention of diketopiperazine formation by
conformationally restricted mobility.
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analogs. In the pursuit of synthesizing thiocoraline prodrugs,
N,N,N0,N0-tetramethylchloroformamidinium hexafluoro-
phosphate (TCFH) was discovered to be a powerful coupling
reagent for bioconjugation that overcomes the problems
associated with the lack of reactivity of the quinaldic alco-
hol.80 This reagent could be useful for the development of
prodrugs for other bisintercalators with similar limitations.
Symmetrical and pseudosymmetrical nucleobase-func-
tionalized triostin A analogs were recently generated by solu-
tion-phase peptide chemistry and found to have the potential
to recognize double-stranded DNA by hydrogen bonding
(see Figure 8).81,82 A series of novel TANDEM derivatives
was also reported.83 Replacement of L-Val at positions 4 and
8 with L-Lys residues was found to have no effect on selectiv-
ity for AT-rich sites whereas replacement of the QXCs by two
naphthoyl chromophores completely abolished binding to
DNA. Changing only one QXC for a naphthalene ring was
found to decrease binding affinity. By combining structural
features of the luzopeptins, triostin A, and thiocoraline,
Albericio and coworkers developed a series of novel cyclic
peptides, FAJANU 1-14 (see Figure 9).84 From these studies,
it has been concluded that (i) larger macrocyclic rings result
in loss of cytotoxic activity, (ii) NMe-Gly is essential to
maintain high cytotoxicity, but NMe-Leu can be replaced by
Leu without considerable effect, (iii) the presence of ester
moieties results in compounds that are less active than mole-
cules with corresponding amide functionalities, and (iv) the
presence of a heteroatom-containing bicyclic chromophore is
required for activity.
Semisynthetic Analogs and Analogs Generated by
Engineered Biosynthesis
The recent identification of the biosynthetic gene clusters of
thiocoraline, echinomycin, triostin A, and SW-163 provided
the opportunity to generate novel bisintercalator derivatives
by chemoenzymatic synthesis and by engineered biosynthesis.
The TE usually found as the C-terminal domain of modular
NRPS catalyzes peptide release through hydrolysis or macro-
cyclization to yield linear or cyclic peptides, respectively. The
TE domains of echinomycin, Ecm7-TE, and of thiocoraline in
a TioS-T-TE construct were utilized to chemoenzymatically
produce bisintercalator analogs from peptidyl-SNAC sub-
strates (see Figure 10).85,86 Using tetrapeptidic-SNACs as
mimics of the tetrapeptides that would be covalently attached
to the thiolation (T) domain of Ecm7 did not lead to the
desired triostin A analogs. However, using similar tetrapep-
tidyl-SNAC precursors with the TioS-T-TE didomain led to
the desired bisintercalators (Figure 10B). These observations
might indicate that the presence of a partner T domain is im-
portant to achieve dimerization prior to macrocyclization. To
obtain the triostin A bisintercalator derivatives, octapeptidyl-
SNAC substrates needed to be used with Ecm7-TE (Figure
10A). It was shown that when using Ecm7-TE, coincubation
with DNA allowed one to efficiently sequester the desired
compounds possessing DNA-binding properties. In addition
to the chemoenzymatic formation of novel bisintercalators by
use of TE domains, an elegant method developed by Oikawa,
Watanabe, Wang, and colleagues resulted in de novo produc-
tion of heterologous bisintercalator antibiotics in E. coli.87,88
In this approach multiple plasmids containing all the genes
required for biosynthesis of the desired compound are trans-
formed into E. coli. The method presents numerous advan-
tages over chemical and chemoenzymatic syntheses: (i) expen-
sive chemicals and time consuming reactions can be avoided,
(ii) the low productivity from the original host can be over-
come as E. coli is easily grown and production in this bacterial
strain has been shown to be efficient upon optimization, and
(iii) genetic manipulations are much simpler in E. coli than in
FIGURE 8 Structures of nucleobase-substituted triostin A analogs.
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other bacterial systems, and (iv) the E. coli platform enables
one to produce metabolites originating from bacteria that are
not amenable to growth in artificial conditions.
RESISTANCE TO BISINTERCALATOR
NATURAL PRODUCTS
The mechanisms by which microorganisms survive the toxic
small molecules they produce can be many. For the bisintercala-
tor natural products two self-resistance mechanisms have been
proposed. First, a UvrA-like protein (TioU, Swb15, TrsM, and
Ecm16), with high sequence homology with the daunorubicin-
resistance-conferring factor DrrC89 and the mithramycin resist-
ance protein MtrX90 could function in repair of chromosomal
damage caused by cytoplasmic bisintercalators prior to their
secretion through the cell membrane. By its introduction into
Escherichia coli BL21 (DE3), Ecm16 was shown to confer echino-
mycin resistance to the E. coli host.45 The role of TioU, Swb15,
and TrsM as self-resistance proteins remains to be confirmed.
An ABC transporter system composed of an ATPase (TioD,
Swb4, and TrsD) and a permease subunit (TioC, Swb5, and
TrsE) is also suggested to be involved in conferring self-resistance
to the producing organism by acting through a transmembrane
secretion mechanism.42–44 Alternatively or additionally, the
bisintercalator compound could be sequestered away by binding
to a protein similar to bleomycin resistance protein. Crystal
structure determination in conjunction with gene knockout and
equilibrium titration studies suggested that TioX from the thio-
coraline cluster, a twofold symmetric tetrameric protein with
homology to a bleomycin resistance protein, but with an un-
usual organization of monomoers, could play this role.91
SUMMARYAND OUTLOOK
Since their discovery, bisintercalator natural products have
intrigued scientists in many distinct, yet complementary,
research areas. Biochemists, biologists, and chemists alike have
been motivated to understand the mode of action of bisinter-
calators as DNA binding ligands and the ways in which Nature
builds these unique structural scaffolds. Research has also been
FIGURE 9 Structures of a set of representative first and second generation FAJANU peptides.
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FIGURE 10 A: Structures of octapeptidyl-SNAC substrates used to generate triostin A analogs. B:
Structures of some bisintercalators generated using the TioS-T-TE didomain.
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directed at generating derivatives of these naturally produced
compounds as novel therapeutics. Their poor solubility and
the complexity associated with their chemical syntheses have
been a cause of concern when considering the development of
new bisintercalator derivatives. However, the production of
novel compounds continues to progress at a fast pace as novel
solid-phase synthesis strategies and reagents are being devel-
oped and discovered. The recent identification of four bisin-
tercalator biosynthetic gene clusters has led to the develop-
ment of novel chemoenzymatic strategies and methods at en-
gineering natural product machineries for production of novel
bisintercalators. It has also contributed significantly to our
current understanding of these compounds and their biosyn-
theses. Many questions yet remain to be answered and further
biochemical studies are needed to fully decipher the exact
functions of the enzymes involved in bisintercalator biosyn-
thesis. Future research should further investigate the pathway
by which the 3HQA chromophore is biosynthesized. The exact
mechanisms that confer resistance to these bisintercalating
agents to their producing organisms also remain to be estab-
lished. New members of this family of compounds have stead-
ily continued to appear. With over a thousand of microbial
genomes sequenced and with the availability of software that
allows one to predict potential structures of molecules of non-
ribosomal peptide origin,92 we can now envision discovering
novel bisintercalators by genome mining. These compounds
are predicted to continue to generate interest for some time to
come in both the academic and industrial settings.
The authors would like to acknowledge the work on bisintercalator
natural products of those not cited in this review due to the scope
of the manuscript. The authors thank Oleg Tsodikov for his insight-
ful comments.
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